Prothena Corporation PLC
NASDAQ:PRTA

Watchlist Manager
Prothena Corporation PLC Logo
Prothena Corporation PLC
NASDAQ:PRTA
Watchlist
Price: 10.34 USD 6.82% Market Closed
Market Cap: $556.6m

Net Margin

-2 379.6%
Current
Declining
by 1 821.1%
vs 3-y average of -558.5%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-2 379.6%
=
Net Income
$-280.5m
/
Revenue
$11.8m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-2 379.6%
=
Net Income
$-280.5m
/
Revenue
$11.8m

Peer Comparison

Country Company Market Cap Net
Margin
IE
Prothena Corporation PLC
NASDAQ:PRTA
556.6m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 98% of companies in Ireland
Percentile
2nd
Based on 314 companies
2nd percentile
-2 379.6%
Low
-6 913.1% — 0%
Typical Range
0% — 10.2%
High
10.2% — 197.7%
Distribution Statistics
Ireland
Min -6 913.1%
30th Percentile 0%
Median 3.1%
70th Percentile 10.2%
Max 197.7%

Prothena Corporation PLC
Glance View

Market Cap
556.6m USD
Industry
Biotechnology

Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. The company is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The firm's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.

PRTA Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-2 379.6%
=
Net Income
$-280.5m
/
Revenue
$11.8m
What is Prothena Corporation PLC's current Net Margin?

The current Net Margin for Prothena Corporation PLC is -2 379.6%, which is below its 3-year median of -558.5%.

How has Net Margin changed over time?

Over the last 3 years, Prothena Corporation PLC’s Net Margin has increased from -3 009.6% to -2 379.6%. During this period, it reached a low of -3 009.6% on Sep 30, 2022 and a high of -23.4% on Jun 30, 2024.

Back to Top